SOD1 and amyotrophic lateral sclerosis: Pre-clinical support for CuII(atsm) in the treatment of ALS is primarily derived from in vivo studies involving mutant SOD1 animal models of the disease1–7, raising questions concerning applicability to the preponderant number of cases which does not involve mutant SOD1.